BioCardia earnings release, August 12, 2026

BioCardia, Inc. (BCDA) · Form 8-K, Item 2.02 · Filed · SEC filing

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

Sunnyvale, Calif. – August 12, 2026 -

BioCardia, Inc.

[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter 2026 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.

“This second quarter, BioCardia had three important positive meetings with regulatory agencies in Japan and the United States,” said Peter Altman, PhD, Chief Executive Officer of BioCardia. “Japan’s Pharmaceutical and Medical Device Agency (PMDA) has said it supports regulatory submission for approval of our CardiAMP Cell Therapy for Ischemic Heart Failure, the U.S. Food and Drug Administration (FDA) has said the CardiAMP HF II trial may be sufficient for approval in the United States, and the FDA has said DeNovo approval of Helix is possible.”

Dr. Altman continued, “We are preparing the CardiAMP cell therapy PMDA submission for the fourth quarter, actively enrolling in the CardiAMP HF II trial, and awaiting FDA minutes on the DeNovo Pre-Submission for approval of the Helix transendocardial delivery catheter held with FDA in May. We are engaged in business development around our cell therapies and separately our experience and technologies for delivery of cardiac biologics which our therapies utilize. We are proud of our demonstrated efficient use of capital while executing on significant goals and expect success in these activities to deliver meaningful benefits for patients and stockholders.”

Recent Business Highlights

CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)

CardiAMP autologous cell therapy in chronic myocardial ischemic with refractory angina (BCDA-02)

Helix™ Biotherapeutic Delivery System

Heart3D™ Fusion Imaging

In April, the Company announced the allowance of Japanese Patent, “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.” This patent adds further protection to BioCardia’s proprietary Heart3D™ Fusion Imaging (Heart3D) software intended for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures. Heart3D is being advanced towards regulatory approval via the software as a medical device 510(k) submission route. It has been in discussions with many developers of gene and cell-based therapies on its potential to enhance others development efforts.

Second Quarter 2026 Financial Results:

ANTICIPATED UPCOMING MILESTONES AND EVENTS:

Conference call access:

Participants can register for the conference by navigating to https://dpregister.com/sreg/10211154/104a4f51d2e. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730 and ask to be connected to the BioCardia call. All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: h ttps://event.choruscall.com/mediaframe/webcast.html?webcastid=ufQzaenK.

A webcast replay of the call will be available approximately one hour after the end of the call at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada) and 1-412-317-0088 (international toll) by using access code 3063624.

About BioCardia®

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO

TM allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix

TM biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D

TM fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies.

The CardiAMP Cell Therapy Trial for Heart Failure has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services.

For more information visit: www.BioCardia.com.

Financial statements

Income Statement

Three Months ended June 30, — (Unaudited in thousands, except share and per share amounts)

Three Months ended June 30, – 2026Three Months ended June 30, – 2025Six Months ended June 30, – 2026Six Months ended June 30, – 2025
Costs and expenses:Research and development8931,3682,1282,898
Costs and expenses:Selling, general and administrative7306831,7611,879
Costs and expenses:Total costs and expenses1,6232,0513,8894,777
Costs and expenses:Operating loss-1,623-2,051-3,889-4,777
Other income (expense):Total other income, net1021716
Other income (expense):Net loss-1,613-2,049-3,872-4,761
Other income (expense):Net loss per share, basic and diluted-0.13-0.4-0.34-0.98
Other income (expense):Weighted-average shares used in computing net loss per share, basic and diluted12,093,2685,059,73611,456,3824,848,922

Balance Sheet

December 31, — (Unaudited in thousands, except share and per share amounts)

June 30, – 2026 (1)December 31, – 2025 (1)
Assets:Cash and cash equivalents4,1172,496
Assets:Other current assets181236
Assets:Property, plant and equipment and other noncurrent assets457681
Assets:Total assets4,7553,413
Liabilities and Stockholders’ EquityCurrent liabilities2,0552,432
Liabilities and Stockholders’ EquityOperating lease liability - noncurrent86
Liabilities and Stockholders’ EquityTotal stockholders’ equity2,700895
Liabilities and Stockholders’ EquityTotal liabilities and stockholders’ equity4,7553,413
Full release

Forward Looking Statements... (truncated)egulatory timelines, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter licensing and partnering arrangements and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent the development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

BioCardia, Inc.

Condensed Consolidated Statements of Operations

(Unaudited in thousands, except share and per share amounts)

(1) June 30, 2026 amounts are unaudited. December 31, 2025 amounts were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on March 24, 2026.

###

Media Contact:

Miranda Peto, Investor Relations

Email: mpeto@BioCardia.com

Phone: 650-226-0120

Investor Contact:

David McClung, Chief Financial Officer

Email: investors@BioCardia.com

Phone: 650-226-0120

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.